These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 27986077)

  • 1. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
    Barlow-Mosha LN; Bagenda DS; Mudiope PK; Mubiru MC; Butler LM; Fowler MG; Musoke PM
    Afr Health Sci; 2012 Sep; 12(3):249-58. PubMed ID: 23382737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
    Tanuma J; Matsumoto S; Haneuse S; Cuong DD; Vu TV; Thuy PTT; Dung NT; Dung NTH; Trung NV; Kinh NV; Oka S
    J Int AIDS Soc; 2017 Dec; 20(4):. PubMed ID: 29211347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Castelnuovo B; Kiragga A; Mubiru F; Kambugu A; Kamya M; Reynolds SJ
    J Int AIDS Soc; 2016; 19(1):20773. PubMed ID: 27319742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
    Rewari BB; Bachani D; Rajasekaran S; Deshpande A; Chan PL; Srikantiah P
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):610-4. PubMed ID: 20890211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
    Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Doran C; Zhang L
    Sex Transm Infect; 2014 Nov; 90(7):538-44. PubMed ID: 24619575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
    Sophan S; Meng CY; Pean P; Harwell J; Hutton E; Trzmielina S; Somasundaran M; Luzuriaga K; Pugatch D
    Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):126-37. PubMed ID: 20578491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.